Liver function may change how olomorasib works – new study investigates
NCT ID NCT06719128
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 study looked at how olomorasib, an oral drug, enters the bloodstream and leaves the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. 46 participants received a single dose. The goal is to understand if liver function affects drug levels, which could guide future dosing. Safety was also monitored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olomorasib (also called LY3537982), an oral drug
What this could lead to
If successful, this study could help doctors decide the right dose of olomorasib for patients with liver problems.
What could go wrong
This is an early, small study focused on drug levels, not on treating a disease. Results may not apply to real-world patients or predict safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Research Corporation at Texas Liver Institute
San Antonio, Texas, 78215, United States
-
Clinical Pharmacology of Miami
Miami, Florida, 33014, United States
-
Orange County Research Center
Lake Forest, California, 92630, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States